Abstract
INTRODUCTION
Colorectal carcinoma (CRC) is the third most common diagnosis and second deadliest malignancy, and meta stasis remains the major cause of mortality in patients with CRC [1, 2] . Deregulated cell motility and invasion is a key initial step in metastasis [3] . Invasive cell migration involves movement through tissues, dynamic interactions with the extracellular matrix, rearrangements of cell tocell contacts and the cytoskeleton [4] . Further under standing of the underlying regulatory mechanisms may provide novel therapeutic regimes for reducing cancer cell dissemination, blocking metastatic progression, and prolonging life expectancy of patients with CRC.
Diaphanousrelated formins (DRFs) are ubiquitously expressed proteins and known to govern cell shape, adhesion, and motility by remodeling the actin cyto skeleton [58] . The DRF protein contains a RhoGTPase binding domain (GBD) in the NH2terminus. Upon binding to a RhoGTPase, the bound NH2terminal diaphanous inhibitory domain is dissociated from the Cterminal diaphanous autoregulatory domain. This, in turn, results in the release of inactive DRF autoinhibition, and subsequently allows the formin homology 2 (FH2) domain to function as the regulator of actin assembly. Three members of the DRFs (DRF1DRF3) were reported to be associated with invadopodia formation and the invasion of breast tumor cells [9] . As the largest family of Rho GTPase effectors, DRFs regulate cytoskeletal remodeling and cancer cell invasion downstream of Rho GTPase signaling. The DRF protein forminlike 2 (FMNL2) drives actinbased protrusion and migration downstream of CDC42 in melanoma cells [10] , and drives the amoeboid invasive cell motility downstream of RhoC [3] . Positive feedback between Dia1, LARG, and RhoA regulates cancer cell morphology and invasion by affecting actin as sembly [11] . Forminlike 3 (FMNL3), another novel member of the DRF family, has been recently identified [12] . Se veral studies have demonstrated the role of FMNL3 in cytoskeletal remodeling and cell migration. FMNL3 participates in filopodia assembly, microtubule acetylation and cellcell adhesion [1315] , as well as induces protein Nmyristoylation required for cellular morphological changes [16] . FMNL3 is also required for the polarized trafficking of podocalyxin to the early apical surface in vascular lumenogenesis, and is a crucial regulator of angiogenesis [17, 18] . Recent studies have demonstrated upregulation of FMNL3 in cutaneous melanoma and nasopharyngeal cancer [19, 20] , as well as its promotion of cancer cell invasion and migration in nasopharyngeal, esophageal carcinoma and neuroblastoma [2022] . Our previous study also indicated that increased expression of FMNL3 contributes to metastasis and poor prognosis in patients with CRC [23] . Although literature on FMNL3 expression and function in multiple tumors has been pre sented, the underlying molecular mechanism of FMNL3 promoting tumor progression and metastasis remains to be elucidated.
Hence, in this study we investigate the effects of FMNL3 on CRC cell proliferation, invasion and migration in vitro using gain and lossoffunction approaches. More over, we reveal an essential role for FMNL3 in regulating the RhoC/FAK pathway and actin assembly dynamics, and the subsequent promotion of CRC invasion.
MATERIALS AND METHODS

Cell lines and reagents
All four CRC cell lines (LOVO, SW620, SW480 and HCT116) and the 293T cell line were purchased from Cell Bank of Chinese Academy of Sciences (Shanghai, China). The cell lines were cultured at 37 ℃ in a 50 mL/L CO2 humidified atmosphere with the appropriate medium according to the requirements of the Cell Bank. Anti (p) Pyk2 (prolinerich tyrosine kinase 2), anti(p) FAK, anti(p) MAPK (Mitogen activated protein kinase), anti (p) AKT and antiRhoC antibodies were purchased from Cell Signaling Technology. Anti-flag, anti-VEGF (vascular endothelial growth factor) and antiFMNL3 antibodies were obtained from Abbkine, Inc (Redlands, CA, United States) and Abnova (Taiwan, China), respectively. For inhibitor treatment, 1 μmol/L TAE226 (Selleck), 20 μmol/ L U0126 (Selleck) or 20 μmol/L Ly294002 (Selleck) was added to the cultured cells for 48 h, respectively.
Construction of plasmids and transfection
Two groups of specific RNA interference sequences targeting the coding regions of FMNL3 and Pyk2 genes were designed as in the previous study [24, 25] . The ones were separately cloned into the GV102 plasmid (Genechem Biotechnology, Shanghai, China) to construct FMNL3 silenced cell lines, named "FMNL3/shRNA1" and "FMNL3/ shRNA2". A scrambled shRNA, which has no homology with the mammalian mRNA sequences, was inserted into the GV102 vector and served as the control. The same method was used to construct the Pyk2silenced cell lines, named "Pyk2/shRNA1" and "Pyk2/shRNA2". To obtain an active mutant construct of RhoCV14, the wildtype coding region of RhoC was amplified by polymerase chain reaction (PCR) and inserted into the expression plasmid pGEX-4T-1. The mutant construct was then generated with the KODPlusMutagenesis Kit (TOYOBO, Japan). The primers were designed as follows: 5'GCTGCAATCCGAAAGAAGCTGGTGA3' or 5' -TCAGAGAATGGGACAGCCCCTCCGA3'. DNA was purified with a Mini plasmid Purification Kit (Qiagen, Japan) and digested with suitable restriction enzymes. DNA fragments were electrophoresed on 1% agarose to verify the insertion of sequences. Cells were plated into 6well plates using 1 × 10 6 cells/well to grow overnight to 90% confluence, and transiently transfected with 3 μg of plasmid using 2 μL Lipofectamine ™ 2000 (Invitrogen, United States) according to the instructions. Cells were incubated for 48 h until they were ready for further as says.
Establishment of cell lines stably expressing FMNL3
Commercialization of the viral particles that express the coding region of the FMNL3 gene, fused EGFP and three flag genes were purchased from GeneCopoeia, 
In vitro invasive assay
The in vitro invasive ability was tested by Boyden cham ber assay. The invasion chamber was equipped with 8 μm pores in polyethylene terephthalate membrane coated with matrigel (BD Biosciences, Foster City, CA, United States). First, 1.5 × 10 5 tumor cells in serumfree RPMI 1640 medium were added to the upper chamber, and the RPMI 1640 with 10% fetal bovine serum was added to the lower chamber as the chemotactic factor. Each cell group was plated in three replicate wells. After incubation for 24 h, the noninvasive cells were gently removed with a cotton swab. Cells that invaded the membrane were fixed with methanol and stained with Giemsa. The number of invaded cells was counted under a light microscope in five random visual fields. The experiment was repeated three times and the average value was calculated.
In vitro scratch assay
The in vitro scratch assay is an easy, lowcost and welldeveloped method to measure cell migration in vitro [26] . Cells were seeded into a 24well plate. When the cells were cultured to confluence, the cell monolayer was scraped in the form of a cross with a formaldehyde, permeabilized with 0.1% Triton X-100 in PBS, and blocked with 1% BSA in PBS for 30 
GST pull-down assay
The recombinant pGEX-4T-1-RhoC-V14 plasmids were transformed into colibacillus BL21 (DE3) and induced for expression by IPTG. SDS-PAGE was used for detection and analysis. Glutathione-Sepharose 4B (GE Hearthcare, Little Chalfont, United Kingdom) affinity chromatography was performed to purify GSTRhoCV14 or GST protein according to the manufacturer's instructions. The purified proteins were then incubated with 293T cell lysates for 2 h at 4 ℃ (293T cells were transfected with the FMNL3 EGFP-3FLAG fusion gene). The Glutathione-Sepharose 4B beads were then washed with icecold PBS, and then bound proteins were eluted and subjected to both electro phoresis and detection with the indicated antibodies.
Statistical analysis
In vitro studies and the quantity of filopodia and lamellipodia were tested using OneWay ANOVAs or ttests. SPSS Statistics 17.0.1 software (SPSS, Chicago, IL, United States) was used for all statistical analyses. P < 0.05 was considered as statistically significant dif ferences.
RESULTS
FMNL3 promotes CRC cell proliferation, invasion and migration in vitro
Our previous study showed lower expression of FMNL3 in low metastatic potential cell lines (HCT116, HT29, LS174T and SW480) than in high metastatic potential plastic pipette tip. Then the three "wound" areas were marked for orientation and photographed by a phase contrast microscope both immediately and after 24 h of incubation. The experiment was repeated three times.
F-actin staining and observation
Cells were seeded into 14 mm Confocal Petri dishes and cultured for 24 h. The cells were then fixed with 40 g/L formaldehyde for 30 min, permeabilized by 0.1% Triton X-100 for 10 min, and then blocked with 1% BSA for 30 min, followed by incubation with 5 μg/mL rhodamine conjugated phalloidin (Sigma, United States) for 1 h. After counterstaining with DAPI, Factin images were acquired with an Olympus FV1000 confocal microscope (Olympus, Japan) using a 100 × oil immersion objective. The length of filopodia and the cells with broad lamellipodia were quantified as in the previous study [18, 24] . The experiment was repeated three times and the average value was calculated.
Western blot assay
Cells were washed twice with cold phosphatebuf fered saline (PBS) and lysed using ice Lysis buffer containing 0.1% protease inhibitors and 0.5% phenyl methanesulfonyl fluoride (Keygen, China). The proteins in the cells were quantified using the bicinchoninic acid method. Fifty micrograms of proteins were loaded onto 10% sodium dodecylpolyacrylamide gel electrophoresis (SDS-PAGE). The proteins were then electro-transferred onto PVDF membranes (Millipore) and blocked in 5% nonfat dry milk in trisbuffered saline. Membranes were immunoblotted overnight at 4 ℃ with antiFMNL3 antibody (Abnova), antiRhoC, antiPyk2 (or pPyk2), antiMAPK (or pMAPK), antiAKT (or pAKT) (Cell signaling technology), anti-VEGF or anti-GAPDH antibody (Abbkine), respectively, and followed by respective horse radish peroxidaseconjugated secondary antibodies (Abbkine). Signals were detected by BeyoECL Plus (Beyotime Biotechnology, China).
Gelatin zymograph assay
Cells were seeded into 6well plates and incubated in serumfree medium for 48 h. The cell supernatant was then collected, and the protein concentration was quantified. The cell supernatant was mixed with 5 × SDS loading buffer followed by electrophoresis on 10% SDS-PAGE containing 0.1% gelatin at 4 ℃. The gel was washed with the eluent (containing 2.5% Triton X-100, 50 mmol/L TrisHCl, 5 mmol/L CaCl2, pH 7.6) for 80 min and rinsed (50 mmol/L TrisHCl, 5 mmol/L CaCl2, pH7.6) for 40 min. The cells were then incubated in the reaction buffer (50 mmol/L TrisHCl, 5 mmol/L CaCl2, 0.02% Brij35, pH 7.6) at 37 ℃ for 42 h, stained with 0.05% coomassie brilliant blue for 3 h, and then destained with buffer containing 30% methanol and 10% acetic acid for 2 h. The image of each band was finally photographed.
Immunofluorescence co-localization assay
For fluorescence staining, cells were fixed with 40 g/L cell lines (LOVO and SW620) [23] . Hence, we chose LOVO and SW620 to construct stable FMNL3knockdown cell lines, as well as HCT116 and SW480 for stable FMNL3 overexpressing cell lines (Figure 1 and Supplementary Figure 1A and B). Then, a series of in vitro assays were performed to detect the effect of FMNL3 expression or silencing on CRC cell proliferation, invasion and migration. MTT assays showed that forced expression of FMNL3 caused a significant increase in the proliferation rate of SW480 and HCT116 cells ( Figure 1C) . Overexpression of FMNL3 also markedly enhanced CRC cell invasion ( Figure 1D ) and migration ( Figure 1E ) by the Boyden chamber assay and scratch assays in vitro, respectively. In contrast, FMNL3depletion showed the opposite ef fects (Supplementary Figure 1) . These data suggest that FMNL3 promotes CRC cell proliferation, invasion and migration in vitro.
FMNL3 regulates the assembly of actin-based protrusions
Next, we observed the effects of FMNL3 overexpression or silencing on the actin cytoskeleton within filopodia and lamellipodia in CRC cells by analysing the rhodamine phalloidin staining of Factin. We found that the filo podia were remarkably more abundant and longer, however the lamellipodia were more narrow in FMNL3 overexpressing cells compared with mock cells (Figure  2A and B) . On the contrary, the filopodia were fewer and shorter but the lamellipodia were wider in 2C). These results were consistent with the findings from other cells in previous studies [13, 18, 24] , and indicated that FMNL3 plays an important role in regulating the assembly of actinbased protrusions.
FMNL3 plays an essential role in the RhoC/FAK pathway to promote CRC cell invasion
To further gain insight into the signaling pathways by which FMNL3 promotes invasive phenotypes, we pre pared cell lysates from FMNL3overexpressing cells, FMNL3depleted cells and the corresponding control cells. As the invasive and metastatic abilities of tumor cells were often correlated with the product of matrix metalloproteinases (MMPs) and VEGF [27, 28] , we measured the expression of these proteins by gelatin zymograph assay and western blot, respectively. Forced expression of FMNL3 significantly caused upregulation of MMP2, MMP-9 and VEGF ( Figure 3A) , and vice versa when FMNL3 was suppressed ( Figure 3B ). Therefore, our results showed that the invasive phenotypes induced by FMNL3 in CRC cells were partly due to the improved expression of MMP-2, MMP-9 and VEGF.
The levels of MMP2 and MMP9 were regulated by phosphorylated MAPK and AKT [29, 30] , which were acti vated by RhoC [3133] or in sequence activated by FAK, Pyk2 and RhoC [25] . Moreover, the expression of VEGF and MMP9 were inhibited by the downregulation of RhoC [28] . More importantly, FMNL3 acts as a downstream effector of RhoC [24] . We thus speculated that FMNL3 participates in a RhoCdependent signaling pathway. To validate this speculation, the expression of pMAPK, pAKT, pFAK, pPyk2 and RhoC in CRC cells was measured by western blot. As shown in Figure 3C , the overexpression of FMNL3 strongly increased the expression of pMAPK, pAKT, pFAK, while FMNL3 silencing generated opposite results ( Figure 3D ). There were no significant differences in the total amounts of these proteins ( Figure 3C and  D) . However, neither overexpression nor depletion of FMNL3 led to any changes in the expressions of pPyk2 and RhoC. These results suggested that FMNL3 may play an essential role in the RhoC signaling pathway, and act downstream of RhoC and ppyk2 as well as upstream of pFAK, pMAPK and pAKT. However, the inhibition of Pyk2 did not affect the expression of FMNL3, although it resulted in the downregulation of pFAK, pMAPK and p-AKT as expected ( Figure 3E ). This suggested that FMNL3 may not work downstream of pPyk2, but only downstream of RhoC. Indeed, when FMNL3/shRNA1 and RhoC genes were transfected simultaneously into SW480 and HCT116 cells, the RhoCdependent upregulations of MMPs and VEGF were partly blocked by FMNL3 silencing ( Figure 4A ). These results confirmed the notion that FMNL3 acts as a downstream effector of RhoC. Thus, FMNL3 may act downstream of RhoC (but not downstream of RhoC and pPyk2) and upstream of pFAK, pMAPK and pAKT. We also investigated the effects of the cotransfection of FMNL3/shRNA1 and RhoC genes on the actin cyto skeleton and invasive abilities of CRC cells. We found that the RhoCdependent restriction of lamellipodial broadening, promotion of filopodia elongation and en hancement of cell invasion were partly inhibited by FMNL3 depletion (Figure 4B and C) . These results sug gested that FMNL3 regulates the assembly of actinbased protrusions and cell invasion of CRC in a RhoCdependent manner.
To further validate the above data, we treated FMNL3-overexpressing cells with TAE226 (a FAK-specific inhibitor), U0126 (a MAPK/ERK-specific inhibitor) or Ly294002 (a PI3K/AKT-specific inhibitor) separately. Then the expressions of MMP2, MMP-9 and VEGF, as well as the difference of cell invasive ability, were measured using the same methods as above. We found that inhibition of FAK, MAPK/ERK or PI3K/AKT indeed significantly blocked the effects of FMNL3induced increases in these three proteins and invasion in CRC cells ( Figure 5 ). These results strongly confirmed the essential role of FMNL3 in the RhoC/FAK signaling pathway.
Taken together, FMNL3 regulates the RhoC/FAK signaling pathway and RhoCdependent remodeling of actinbased protrusions to promote CRC invasion.
FMNL3 interacts directly with RhoC
Finally, we explored the partner of FMNL3 in the RhoC/ FAK signaling pathway. Since FMNL3 belongs to the DRF subfamily and contains a GBD domain in the NH2 terminus, it provides the structural basis for the activation by RhoGTPases via direct binding. The possibility of the interaction between FMNL3 and RhoC was therein tested by co-immunoprecipitation, immunofluorescencebased confocal microscopy and GSTpull down assays. Indeed, we found that FMNL3 and RhoC colocalized in the cytoplasm ( Figure 6A ), and immunoprecipitated with each other by one or the other antibody ( Figure  6B ). The results of GST pull-down assays confirmed the direct binding of FMNL3 to RhoC in vitro ( Figure 6C ). These results demonstrated that FMNL3 interacts directly with RhoC in vivo and in vitro, which were in accordance with the findings of the Vega FM group regarding the interaction between FMNL3 and RhoC in vitro [24] .
DISCUSSION
We have shown in previous studies that increased FMNL3 expression contributes to metastasis and poor prognosis in patients with CRC [23] . However, the underlying mole cular mechanism remains unclear. In this study, we explored the possible signaling pathway responsible for CRC cell invasion and migration induced by FMNL3. We first determined the biological effects of FMNL3 on CRC cells in vitro. Our results showed the positive roles of FMNL3 in CRC cell proliferation, migration and invasion in vitro, which were inconsistent with the promotion of FMNL3 in tumor growth and metastasis in vivo found in our previous study [23] . Recent studies have also reported the relevant function of FMNL3 in tumor cell growth and proliferation [34] . Other DRF members were also involved in cell proliferation and division through cell cycle regulation [35] or microtubule stabilization in a cell type selective manner [36] . Moreover, FMNL3 has been shown to promote cell invasion, migration and metastasis in various cell types [1922] , confirming our previous and present study results both in vivo and in vitro [23] . Previous studies have reported that the reorganization of the actin cytoskeleton is responsible for enhanced cell motility that is necessary for cancer cell invasion and metastasis [4] . As a RhoGTPasebinding protein, DRF possesses conserved function in actin cytoskeletal dynamics exerted through the formin homology 2 (FH2) domain [37] . DRF contains a NH2terminal GBD domain, where upon binding to a RhoGTPase, the bound NH2 terminal diaphanous inhibitory domain dissociates from the COOHterminal diaphanous autoregulatory domain. This, in turn, results in the release of inactive DRF auto inhibition and subsequently allows the FH2 domain to function as a direct regulator of actin polymerization [37] . DRFs are major actin filament nucleators, which can bundle linear actin filaments and generate membrane protrusions such as filopodia and lamellipodia [38, 39] . Here, we found that FMNL3 overexpression promotes the elongation of filopodia and restricts the broadening of lamellipodia. Some researchers have also reported the assembly of filopodia and lamellipodia by FMNL3 [13, 22, 24] and verified the structure of the FMNL3 FH2/actin complexmediated actin nucleation and elongation [40] . Evidence has shown that DRFs regulate the assembly of actinrelated structures and cancer cell invasion down stream of Rho GTPases [911, 41] . Rho family GTPases, including RhoA, RhoB, RhoC, Rac and Cdc42, are key regulators of actin cytoskeletal dynamics associated with cell motility and invasion, and their expression and acti vation generally increase with tumor progression [42, 43] . RhoC is the bestcharacterized Rho GTPase among them, and its overexpression has recently been shown to be closely linked with highly invasive and metastatic forms of many human cancers [44] . Recent studies have also reported that RhoC promotes polarized migration through FMNL3 by restricting the lamellipodia broadening in prostate cancer [24] . Our results also showed that FMNL3 could regulate the actinbased protrusions of filopodia and lamelipodia in a RhoC-dependent manner to accelerate CRC cell invasion. These results were con sistent with the findings of the Higgs HN and Ridley AJ groups regarding the roles of FMNL3 in the regulation of 
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filopodia and lamellipodia that contribute to the enhanced migratory and invasive potential in other cell types [13, 18, 24] . The molecular mechanism by which FMNL3 promotes tumor progression and metastasis is a fascinating sub ject. Evidence has shown that RhoC is closely related to the high invasion and metastasis of various types of human cancers [44] . RhoC induces tumor cell motility and invasion via MAPK and PI3K/AKTdependent path ways [25, 3133] . However, whether FMNL3 regulates the RhoCdependent signaling pathway to promote CRC cell invasion and migration needs further investigation.
MMP-2, MMP-9 and VEGF are important effectors of the RhoCdependent pathway [25, 28, 45] . Moreover, MMP2 and MMP9 are the two key proteases for tumor meta stasis [27] . VEGF is one of the important angiogenetic factors required for tumor angiogenesis [46] . Our results provide evidence for the role of FMNL3 in activation of the two proteases and VEGF in CRC cells, suggesting a possible role of FMNL3 in RhoCdependent pathway activation during CRC cell invasion.
Both MMP2 and MMP9 were shown to be activated by phosphorylated MAPK and AKT [29, 30] . In addition, MAPK and AKT signaling pathways were activated by RhoC [3133] or in sequence by FAK, Pyk2 and RhoC [25] . Moreover, RhoC expression levels are correlated with the expressions levels of VEGF and MMP9 [28] . In addition, p-FAK regulates VEGFR2 transcription in angiogenesis [47] . Our study shows that FMNL3
induced the phosphorylation of FAK and subsequent phosphorylation of MAPK and AKT, resulting in the upregulation of MMP-2, MMP-9 and VEGF, and the subsequent promotion of enhanced CRC cell invasion. FAK is a protein tyrosine kinase that was first identified within the extracellular matrix and at integrin receptor cell adhesion sites, and is a key regulator of cell movement [48] . Resent studies showed increased expression of pFAK in the nuclei of cells in laryngeal cancer and four digestive cancers, including colorectal cancer [49, 50] . Nuclear FAK promotes cell proliferation and survival through enhanced P53 degradation [51] , suggesting an association between pFAK and abnormal cell proliferation. In addition, nuclear expression of pFAK is also associated with poor prognosis in colorectal cancer [52] . In this study, we found that the phosphorylation of FAK (triggered by RhoC/FMNL3 signaling) induced the activation of MAPK and AKT 
+ -
and the subsequent upregulation of MMPs and VEGF, and contributed to the invasive potential of CRC cells. Of course, it may also be correlated with the nuclear location of pFAK, which is triggered by RhoC/FMNL3 signaling. Other studies also presented the correlation of DRF members with MAPK, AKT and/or FAK, as well as Rho signaling [3, 10, 53, 54] . The DRF FMNL2 enhanced CRC cell invasion via the MAPK/ERK and PI3K/AKT pathways [53] , and regulated the invasive cell motility and migration downstream of RhoC and Cdc42 [3, 10] . Another DRF member, mDia1, acts downstream of RhoA and upstream of MAPK, ERK and FAK to induce intestinal epithelial cell migration [54] . Finally, we uncovered RhoC as the partner of FMNL3 in the RhoC/FAK signaling pathway by coIPs, immuno fluorescence co-localization experiments and GST pulldown assays. This finding was also supported by the structural basis of the GBD domain in the Nterminus of FMNL3, and has also been verified by the GST pulldown assay from the Ridley AJ group [24] . However, other groups reported the interaction of FMNL3 with Cdc42 or RhoJ, and proposed that FMNL3 is a downstream effector of Cdc42 or RhoJ to promote the filopodial outgrowth during endothelial lumen formation [17, 55] . Unfortunately, there was a limitation to our present study, as there may be crosstalk between RhoC and other small GTPasebinding proteins such as Cdc42 and RhoJ during FMNL3dependent CRC cell invasion. This thus needs further investigation.
In conclusion, FMNL3 plays a positive role in CRC cell proliferation, invasion and migration. In addition, FMNL3 activates the RhoC/FAK signaling pathway via its interaction with RhoC, and regulates RhoCdependent remodeling of actin-based protrusions, such as filopodia and lamellipodia, to promote CRC cell invasion. FMNL3 can be applied as a promising specific biomarker for CRC progression and metastasis.
ARTICLE HIGHLIGHTS
Research background
Formin-like 3 (FMNL3) is a novel member of the diaphanous-related formins subfamily, which act as downstream effectors of Rho-GTPase signaling and regulate actin-dependent processes, such as cell motility and invasion. Increased expression of FMNL3 has been identified to contribute to metastasis and the poor prognosis of colorectal carcinoma (CRC). However, the exact molecular mechanism by which FMNL3 promotes CRC cell invasion and metastasis remains ambiguous. Therefore, elucidation of the underlying mechanism may help to block the metastatic progression and improve the survival rate of patients with CRC.
Research motivation
It is necessary to explore whether FMNL3 regulates Rho GTPase signaling to affect cytoskeletal organization and subsequent CRC cell invasion. Recent studies have demonstrated FMNL3 in reorganization of actin-dependent protrusions, such as filopodia and lamellipodia. The potential role of FMNL3 in tumor cell invasion and metastasis has also been reported in several tumor types. Moreover, FMNL3 acts as a downstream effector of RhoC to promote prostate cancer invasion by controlling lamellipodia. These findings give us a good lead for further study regarding the mechanism of FMNL3 regulation during CRC cell invasion and metastasis.
Research objectives
In this study, we investigate the effects of FMNL3 on CRC cell proliferation, invasion and migration in vitro by gain-and loss-of -function approaches. Moreover, we explore the role of FMNL3 in the RhoC-dependent signaling pathway and actin assembly dynamics, and the relation with CRC cell invasion. Our study provides significant insights into the signaling mechanism of FMNL3 during CRC invasion that may contribute to the future design of more effective metastasis-related therapies.
Research methods
Experiments using gene transfection or silencing were conducted to construct FMNL3 stably-expressed or -depleted cell lines to complete the following functional studies. A series of in vitro experiments, such as MTT, transwell chamber and scratch assays, were performed to explore the effects of FMNL3 on cell proliferation, invasion and migration. Rhodamine-conjugated phalloidin staining and confocal microscopy was used to display and observe F-actin dependent protrusions, such as filopodia and lamellipodia. Western blots and gelatin zymography assays were carried out to explore how the signaling pathway of FMNL3 is involved in CRC invasion. The key inhibitors of the RhoC/ FAK pathway were used to treat CRC cells to verify the reliability of the signaling mechanism. In addition, the experiments involving immunofluorescence colocalization, co-immunoprecipitation and GST-pull downs were performed to unveil the partner of FMNL3 in the signaling pathway.
Research results
The results of in vitro experiments showed a positive role of FMNL3 in cell proliferation, invasion and migration of CRC. Rhodamine-conjugated phalloidin staining and confocal microscopy-based observations demonstrated that FMNL3 induced the elongation of filopodia, but inhibited the broadening of lamellipodia in a RhoC-dependent manner to enhance the invasive abilities of CRC cells. In addition, the results of western blots and gelatin zymography assays suggested that FMNL3 was involved in the RhoC/FAK signaling pathway and acted as an effector of RhoC to activate the downstream signaling of p-FAK as well as p-MAPK and p-AKT. This was followed by the increased expression of MMP-2, MMP-9 and VEGF, resulting in the promotion of CRC cell invasion. The results of inhibitor treatments confirmed the essential role of FMNL3 in the activation of the RhoC/FAK pathway and the subsequent promotion of CRC cell invasion. A direct interaction of FMNL3 with RhoC in vivo and in vitro was displayed by co-IP, co-localization and GST-pull down analyses.
Research conclusions
In conclusion, FMNL3 plays a positive role in CRC cell proliferation, invasion and migration. In addition, FMNL3 activates the RhoC/FAK signaling pathway via its interaction with RhoC. FMNL3 also regulates RhoC-dependent remodeling of actin-based protrusions, such as filopodia and lamellipodia, to promote CRC cell invasion. FMNL3 can be applied as a promising specific biomarker for CRC progression and metastasis.
Research perspectives
Our study illuminates the role and molecular mechanism of FMNL3 in the regulation of CRC invasion, and revealed RhoC's involvement in the RhoC/ FAK signaling pathway as the partner of FMNL3. Other groups reported the interaction of FMNL3 with Cdc42 or RhoJ, and proposed that FMNL3 acted as a downstream effector of Cdc42 or RhoJ to promote the filopodia outgrowth during endothelial lumen formation. There may be cross-talk between RhoC and other small GTPase proteins, such as Cdc42 and RhoJ, to coordinate the regulation of FMNL3-dependent CRC cell invasion. This, however, needs further investigation.
